Concepedia

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

David Qualls, Nicholas Lambert, Paolo F. Caimi, Mwanasha H. Merrill, Priyanka Pullarkat, Richard Godby, David A. Bond, Graham T. Wehmeyer, Jason T. Romancik, Behzad Amoozgar,

Blood · 2023 · 46 citations · 4 references

DOIFull text

Open access

Concepts

Abstract

ABSTRACT: In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.

References

4

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Gilles Salles, Johannes Duell, Eva González‐Barca et al. · The Lancet Oncology · 2020 · 519 citations · Full text

, , +10

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Johannes Duell, Kami J. Maddocks, Eva González‐Barca et al. · Haematologica · 2021 · 140 citations · Full text

, , +12

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Wojciech Jurczak, Pier Luigi Zinzani, Gianluca Gaïdano et al. · Blood · 2019 · 26 citations

, , +13

Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC

Ulrike Paul, Julia Richter, Christiane Stuhlmann-Laiesz et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2017 · 24 citations

, , +16